Disruption of the histone acetyltransferase MYST4 leads to a noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice

Journal of Clinical Investigation

Volumn 121, Issue 9, 2011, Pages 3479-3491

  Kraft, Michael ^a   Cirstea, Ion Cristian ^b   Voss, Anne Kathrin ^c,d   Thomas, Tim ^c,d   Goehring, Ina ^a   Sheikh, Bilal N ^c,d   Gordon, Lavinia ^c   Scott, Hamish ^c,d,i   Smyth, Gordon K ^c,d   Ahmadian, Mohammad Reza ^b   Trautmann, Udo ^a   Zenker, Martin ^a,e   Tartaglia, Marco ^f   Ekici, Arif ^a   Reis, André ^a   Dörr, Helmuth Guenther ^g   Rauch, Anita ^a,h   Thiel, Christian Thomas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE MYST4; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CHILD; CHROMOSOME MAP; CLINICAL FEATURE; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HAPLOINSUFFICIENCY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LEARNING DISORDER; MALE; MORPHOGENESIS; MOUSE; NONHUMAN; NOONAN SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PTOSIS; SHORT STATURE; SIGNAL TRANSDUCTION;

ANIMALS; CHILD; CHROMOSOME MAPPING; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; GENE KNOCKDOWN TECHNIQUES; HAPLOINSUFFICIENCY; HELA CELLS; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOGENESIS; NOONAN SYNDROME; PHENOTYPE; PROTEIN ISOFORMS; RNA, SMALL INTERFERING;

EID: 80052353444     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43428     Document Type: Article

References (55)

1. Kornberg R.D., Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999;98(3):285-294. (Pubitemid 29380564)
2. MacDonald V.E., Howe L.J. Histone acetylation: Where to go and how to get there. Epigenetics. 2009; 4(3):139-143.
3. Ekwall K. Genome-wide analysis of HDAC function. Trends Genet. 2005;21(11):608-615. (Pubitemid 41429289)
4. Fraga M.F., Esteller M. Towards the human cancer epigenome: A first draft of histone modifications. Cell Cycle. 2005;4(10):1377-1381. (Pubitemid 41437126)
5. Urdinguio R.G., Sanchez-Mut J.V., Esteller M. Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies. Lancet Neurol. 2009;8(11):1056-1072.
6. Thomas T., Dixon M.P., Kueh A.J., Voss A.K. Mof (MYST1 or KAT8) is essential for progression of embryonic development past the blastocyst stage and required for normal chromatin architecture. Mol Cell Biol. 2008;28(16):5093- 5105.
7. Choudhary C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834-840.
8. Tartaglia M., Zampino G., Gelb B.D. Noonan syndrome: Clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1(1):2-26.
9. Van der Burgt I. Noonan syndrome. Orphanet J Rare Dis. 2007;2:4.
10. Burge C., Karlin S. Prediction of complete gene structures in human genomic DNA. J Mol Biol. 1997;268(1):78-94. (Pubitemid 27192680)
11. Borrow J., et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 1996;14(1):33-41.
12. Reifsnyder C., Lowell J., Clarke A., Pillus L. Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases. Nat Genet. 1996;14(1):42-49.
13. Voss A.K., Thomas T. MYST family histone acetyltransferases take center stage in stem cells and development. Bioessays. 2009;31(10):1050-1061.
14. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 2004;32(3):959-976.
15. Yang X.J., Ullah M. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene. 2007;26(37):5408-5419. (Pubitemid 47255923)
16. Champagne N., et al. Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. J Biol Chem. 1999;274(40):28528-28536.
17. Thomas T., Voss A.K., Chowdhury K., Gruss P. MYST family histone acetyltransferase, is required for normal cerebral cortex development. Development. 2000;127(12):2537-2548. (Pubitemid 30426802)
18. Miller C.T., Maves L., Kimmel C.B. MOZ regulates Hox expression and pharyngeal segmental identity in zebrafish. Development. 2004;131(10):2443-2461. (Pubitemid 38877651)
19. Pelletier N., Champagne N., Stifani S., Yang X.J. MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. Oncogene. 2002;21(17):2729-2740. (Pubitemid 34478331)
20. Thomas T., et al. Monocytic leukemia zinc finger protein is essential for the development of longterm reconstituting hematopoietic stem cells. Genes Dev. 2006;20(9):1175-1186.
21. Thomas T., Voss A.K. Querkopf, a histone acetyltransferase, is essential for embryonic neurogenesis. Front Biosci. 2004;9:24-31. (Pubitemid 38925435)
22. Voss A.K., Collin C., Dixon M.P., Thomas T. Moz and retinoic acid coordinately regulate H3K9 acetylation, Hox gene expression, and segment identity. Dev Cell. 2009;17(5):674-686.
23. Merson T.D., et al. The transcriptional coactivator Querkopf controls adult neurogenesis. J Neurosci. 2006;26(44):11359-11370. (Pubitemid 44772165)
24. Rietze R.L., Valcanis H., Brooker G.F., Thomas T., Voss A.K., Bartlett P.F. Purification of a pluripotent neural stem cell from the adult mouse brain. Nature. 2001;412(6848):736-739. (Pubitemid 32771996)
25. Lee K.K., Workman J.L. Histone acetyltransferase complexes: One size doesn't fit all. Nat Rev Mol Cell Biol. 2007;8(4):284-295. (Pubitemid 46474661)
26. Kanehisa M., et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008; 36(Database issue):D480-D484. (Pubitemid 351149770)
27. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37-40. (Pubitemid 32225829)
28. Nishida E., Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci. 1993;18(4):128-131. (Pubitemid 23105313)
29. Pearson G., et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev. 2001;22(2):153-183. (Pubitemid 32458157)
30. Cirstea I.C., et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 2010;42(1):27-29.
31. Rodriguez-Viciana P., Oses-Prieto J., Burlingame A., Fried M., McCormick F. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell. 2006;22(2):217-230.
32. Bobick B.E., Kulyk W.M. Regulation of cartilage formation and maturation by mitogen-activated protein kinase signaling. Birth Defects Res C Embryo Today. 2008;84(2):131-154. (Pubitemid 351957224)
33. Corson L.B., Yamanaka Y., Lai K.M., Rossant J. Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development. 2003; 130(19):4527-4537. (Pubitemid 37279407)
34. Kawakami Y., et al. MKP3 mediates the cellular response to FGF8 signalling in the vertebrate limb. Nat Cell Biol. 2003;5(6):513-519. (Pubitemid 36781084)
35. Keren A., Tamir Y., Bengal E. The p38 MAPK signaling pathway: A major regulator of skeletal muscle development. Mol Cell Endocrinol. 2006;252(1-2):224-230.
36. Takeda K., Ichijo H. Neuronal p38 MAPK signalling: An emerging regulator of cell fate and function in the nervous system. Genes Cells. 2002; 7(11):1099-1111. (Pubitemid 35264519)
37. Gonzalez I., et al. Akt2, a novel functional link between p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in myogenesis. Mol Cell Biol. 2004;24(9):3607-3622. (Pubitemid 38496142)
38. Fuentealba L.C., et al. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/ Smad1 signal. Cell. 2007;131(5):980-993. (Pubitemid 350138081)
39. Li B. Bone morphogenetic protein-Smad pathway as drug targets for osteoporosis and cancer therapy. Endocr Metab Immune Disord Drug Targets. 2008;8(3):208-219.
40. Kojima K., et al. A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13). Br J Haematol. 2003;120(2):271-273. (Pubitemid 36194176)
41. Moore S.D., et al. Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. Cancer Res. 2004;64(16):5570-5577. (Pubitemid 39095551)
42. Panagopoulos I., et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum Mol Genet. 2001; 10(4):395-404. (Pubitemid 32166550)
43. Van Beekum O., Kalkhoven E. Aberrant forms of histone acetyltransferases in human disease. Subcell Biochem. 2007;41:233-262.
44. Shaw A.C., Kalidas K., Crosby A.H., Jeffery S., Patton M.A. The natural history of Noonan syndrome: A long-term follow-up study. Arch Dis Child. 2007;92(2):128-132.
45. Sznajer Y., et al. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene. Pediatrics. 2007;119(6):e1325- e1331. (Pubitemid 46871252)
46. Zenker M., et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet. 2007;44(2):131-135.
47. Roberts A.E., et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007;39(1):70-74. (Pubitemid 46026503)
48. Huangfu D., et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26(7):795-797. (Pubitemid 351961456)
49. Marchion D., Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 2007;7(4):583-598. (Pubitemid 46690964)
50. Wiech N.L., Fisher J.F., Helquist P., Wiest O. Inhibition of histone deacetylases: A pharmacological approach to the treatment of non-cancer disorders. Curr Top Med Chem. 2009;9(3):257-271.
51. Kaufman M. The Atlas Of Mouse Development. New York, New York, USA: Academic Press; 1995.
52. Voss A.K., Thomas T., Gruss P. Efficiency assessment of the gene trap approach. Dev Dyn. 1998; 212(2):171-180. (Pubitemid 28265138)
53. Voss A.K., Thomas T., Gruss P. Mice lacking HSP- 90beta fail to develop a placental labyrinth. Development. 2000;127(1):1-11. (Pubitemid 30064383)
54. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
55. Smyth G.K., Michaud J., Scott H.S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21(9):2067-2075. (Pubitemid 40668046)